Insider Transactions in Q2 2023 at Myriad Genetics Inc (MYGN)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 02
2023
|
Daniel K Spiegelman Director |
SELL
Open market or private sale
|
Direct |
8,638
-17.58%
|
$198,674
$23.01 P/Share
|
|
Jun 01
2023
|
Rashmi Kumar Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,151
+17.96%
|
-
|
|
Jun 01
2023
|
Paul Bisaro Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,575
+23.65%
|
-
|
|
Jun 01
2023
|
Daniel K Spiegelman Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,151
+23.57%
|
-
|
|
Jun 01
2023
|
Daniel Skovronsky Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,151
+17.73%
|
-
|
|
Jun 01
2023
|
Colleen F Reitan Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,151
+17.22%
|
-
|
|
Jun 01
2023
|
Heinrich Dreismann Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,151
+11.56%
|
-
|
|
Jun 01
2023
|
Lee Nisley Newcomer Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,151
+17.22%
|
-
|
|
Jun 01
2023
|
S. Louise Phanstiel Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,151
+11.92%
|
-
|
|
Apr 14
2023
|
Dale Muzzey Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
638
-0.93%
|
$14,036
$22.27 P/Share
|
|
Apr 14
2023
|
Mark Verratti Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
703
-0.27%
|
$15,466
$22.27 P/Share
|